Chinese drug manufacturer with CCP ties imported unauthorized GLP-1 drug ingredients
Until that point, two batches of the rebranded semaglutide, distributed to the U.S. in August and October 2025, were in commercial circulation within the U.S. With a Class II risk-level designation of “moderate to high risk,” the FDA warns that consumption of such recalled products “may cause temporary or medically reversible adverse health consequences.”Harbin Jixianglong Biotech has reported ties to the Harbin Institute of Technology, which the U.S. Department of Commerce identified as a security risk for attempting to acquire U.S. technology for Chinese missile programs.
- ▪Until that point, two batches of the rebranded semaglutide, distributed to the U.S. in August and October 2025, were in commercial circulation within the U.S.
- ▪With a Class II risk-level designation of “moderate to high risk,” the FDA warns that consumption of such recalled products “may cause temporary or medically reversible adverse health consequences.”Harbin Jixianglong Biotech has reported ti
- ▪Department of Commerce identified as a security risk for attempting to acquire U.S. technology for Chinese missile programs.
Opening excerpt (first ~120 words) tap to expand
Federal investigators say that a Chinese drug manufacturer, previously on the Food and Drug Administration’s list of preapproved foreign companies allowed to import GLP-1 ingredients, was able to bring in batches of the weight loss drug from an unauthorized supplier and introduce the substance of unknown origin into the U.S. drug supply.In September 2025, now-ousted FDA Commissioner Marty Makary launched a so-called “green list” of overseas facilities permitted to ship active pharmaceutical ingredients for GLP-1 medication into the United States. The list is meant to prevent “potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
